Aiming to Improve Readmissions Through InteGrated Hospital Transitions (AIRTIGHT): a Pragmatic Randomized Controlled Trial
Despite years of intense focus, inpatient and observation readmission rates remain high and largely unchanged. Hospitals have little, robust evidence to guide the selection of interventions effective at reducing 30-day readmissions in real-world settings.
To evaluate if implementation of recent recommendations for hospital transition programs is effective at reducing 30-day readmissions in a population discharged to home and at high-risk for readmission.
A non-blinded, pragmatic randomized controlled trial (Clinicaltrials.gov: NCT02763202) conducted at two hospitals in Charlotte, North Carolina.
A total of 1876 adult patients, under the care of a hospitalist, and at high risk for readmissions.
Random allocation to a Transition Services (TS) program (n = 935) that bridges inpatient, outpatient, and home settings, providing patients virtual and in-person access to a dedicated multidisciplinary team for 30-days, or usual care (n = 941).
Thirty-day, unplanned, inpatient, or observation readmission rate.
The 30-day readmission rate was 15.2% in the TS group and 16.3% in the usual care group (RR 0.93; 95% [CI, 0.76 to 1.15]; P = 0.52). There were no significant differences in readmissions at 60 and 90 days or in 30-day Emergency Department visit rates. Patients, who were referred to TS and readmitted, had less Intensive Care Unit admissions 15.5% vs. 26.8% (RR 0.74; 95% [CI, 0.59 to 0.93]; P = 0.02).
An intervention inclusive of contemporary recommendations does not reduce a high-risk population’s 30-day readmission rate. The high crossover to usual care (74.8%) reflects the challenge of non-participation that is ubiquitous in the real-world implementation of population health interventions.
KEY WORDSreadmissions population health outcomes research healthcare value pragmatic research
Primary Funding Source
Carolinas HealthCare System
Compliance with Ethical Standards
The trial was approved by the Carolinas HealthCare System Institutional Review Board and granted a waiver for patient consent (reference number 01-15-10E).
Conflict of Interest
AM has received funding support for research from AstraZeneca, Amylin Pharmaceuticals, and is a cofounder of iEnroll, LLC. No other authors report any potential conflicts of interest.
- 5.Rennke S, Nguyen OK, Shoeb MH, Magan Y, Wachter RM, Ranji SR. Hospital-initiated transitional care interventions as a patient safety strategy: a systematic review. Ann Intern Med. 2013;158(5 Pt 2):433–40. https://doi.org/10.7326/0003-4819-158-5-201303051-00011.CrossRefPubMedGoogle Scholar
- 6.Kansagara D, Chiovaro JC, Kagen D, Jencks S, Rhyne K, O'Neil M, et al. So many options, where do we start? An overview of the care transitions literature. J Hosp Med. 2015. https://doi.org/10.1002/jhm.2502.
- 8.Hansen LO, Young RS, Hinami K, Leung A, Williams MV. Interventions to reduce 30-day rehospitalization: a systematic review. Ann Intern Med. 2011;155(8):520–8. https://doi.org/10.7326/0003-4819-155-8-201110180-00008.CrossRefPubMedGoogle Scholar
- 9.Leppin AL, Gionfriddo MR, Kessler M, Brito JP, Mair FS, Gallacher K, et al. Preventing 30-day hospital readmissions: a systematic review and meta-analysis of randomized trials. JAMA Intern Med. 2014;174(7):1095–107. https://doi.org/10.1001/jamainternmed.2014.1608.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Low LL, Tan SY, Ng MJ, Tay WY, Ng LB, Balasubramaniam K, et al. Applying the Integrated Practice Unit Concept to a Modified Virtual Ward Model of Care for Patients at Highest Risk of Readmission: A Randomized Controlled Trial. PLoS One. 2017;12(1):e0168757. https://doi.org/10.1371/journal.pone.0168757.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.School HB. Integrated Practice Unit. http://www.isc.hbs.edu/health-care/vbhcd/Pages/integrated-practice-units.aspx. Accessed July 2018.
- 16.McWilliams A, Roberge J, Moore CG, Ashby A, Rossman W, Murphy S, et al. Aiming to Improve Readmissions Through InteGrated Hospital Transitions (AIRTIGHT): study protocol for a randomized controlled trial. Trials. 2016;17(1):603. https://doi.org/10.1186/s13063-016-1725-2.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.SAS Enterprise Guide 6.1 for Windows on platform 9.4.1,. Cary, NC: SAS Institute Inc.Google Scholar